Previous close | 724.10 |
Open | 725.10 |
Bid | 0.00 x N/A |
Ask | 714.30 x N/A |
Day's range | 712.90 - 725.10 |
52-week range | 386.40 - 736.00 |
Volume | |
Avg. volume | 12 |
Market cap | 681.413B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 111.92 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.75 (0.66%) |
Ex-dividend date | 14 Feb 2024 |
1y target est | N/A |
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.